# EDGAR Filing Document

**Accession Number:** 0001754068
**File Stem:** 0001193125-26-149595
**Filing Date:** 2026-4
**Character Count:** 2309
**Document Hash:** 3a33af5c5abc7579883a0d3481b8ffa0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-149595.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001193125-26-149595

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kalaris Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001754068
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831971007
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 400 CONNELL DRIVE
- **STREET 2:** SUITE 5500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 650-249-2727

**MAIL ADDRESS:**
- **STREET 1:** 400 CONNELL DRIVE
- **STREET 2:** SUITE 5500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Allovir, Inc.
- **DATE OF NAME CHANGE:** 20190521

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ViraCyte, Inc.
- **DATE OF NAME CHANGE:** 20180924

April 9, 2026

**<u>VIA EDGAR SUBMISSION</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance, Office of Life Sciences

100 F Street, NE

Washington, DC 20549

Attention: Chris Edwards

Re: Kalaris Therapeutics, Inc.

Registration Statement on Form S-3

Filed April 3, 2026

File No. 333-294881

<u>Request for Acceleration</u>

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kalaris Therapeutics, Inc. (the "**Registrant**") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-294881), so that it may become effective at 4:00 p.m., Eastern Time, on April 13, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the U.S. Securities and Exchange Commission.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Kalaris Therapeutics, Inc. | Kalaris Therapeutics, Inc. |
| By: | /s/ Andrew Oxtoby |
| Name: Andrew Oxtoby | Name: Andrew Oxtoby |
| Title: President and Chief Executive Officer | Title: President and Chief Executive Officer |

---